• FirefoxInstall the new Firefox »
  •  Dow Down 0.45% Nasdaq Down 0.49%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    101.53 Down 2.86(2.74%) Feb 27, 4:00PM EST
    |After Hours : 102.31 Up 0.78 (0.77%) Feb 27, 6:21PM EST
    Add to Portfolio
    Prev Close:104.39
    Open:104.80
    Bid:102.00 x 500
    Ask:N/A
    1y Target Est:132.13
    Beta:1.95
    Earnings Date:May 6 - May 11 (Est.)
    Day's Range:100.03 - 105.48
    52wk Range:47.03 - 111.49
    Volume:574,929
    Avg Vol (3m):715,028
    Market Cap:8.50B
    P/E (ttm):N/A
    EPS (ttm):-4.85
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Comparison

    Symbol% ChgMkt Cap
    ALNYDown 2.74%8.50B
    MRKDown 0.71%166.89B
    PFEDown 0.78%216.24B
    VRXDown 1.87%66.29B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):172.93
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-3.05
    Quarterly EPS Est (Mar-15) :-0.66
    Mean Recommendation*:2.0
    PEG Ratio (5 yr expected):-0.72

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback